The first clinical presentation of multiple sclerosis (MS) is usually a single episode of typical symptoms and signs and is designated a "first clinical demyelinating event" (FCDE) or a "clinically isolated syndrome". Patients with an FCDE who show 'silent' magnetic resonance imaging lesions are at high risk of further clinical events and therefore of meeting the criteria for the diagnosis of clinically definite MS (CDMS). Here we review five Phase III trials, in which treatment with the following disease-modifying drugs (DMDs) was initiated at this early stage: interferon beta (ETOMS, CHAMPS, BENEFIT, and REFLEX) and glatiramer acetate (PreCISe). Differences in the design of the trials and their patient inclusion criteria limit comparisons. However, the proportion of placebo-treated patients who developed CDMS within 2 years was 38-45% across studies, and this rate was significantly reduced by DMD treatment. Conversion to McDonald MS was reported by only two of the trials: BENEFIT (2001 criteria) and REFLEX (2005 criteria). Around 85% of placebo-treated patients developed McDonald MS by 2 years in each, and again a beneficial effect of DMD treatment was seen. Overall, these studies support early use of DMDs to treat patients with an FCDE who are at high risk of conversion to CDMS. © 2013 The Authors.

Freedman, M.S., Comi, G., De Stefano, N., Barkhof, F., Polman, C.H., Uitdehaag, B.M.J., et al. (2014). Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 3(2), 147-155 [10.1016/j.msard.2013.07.001].

Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice

De Stefano, Nicola;
2014-01-01

Abstract

The first clinical presentation of multiple sclerosis (MS) is usually a single episode of typical symptoms and signs and is designated a "first clinical demyelinating event" (FCDE) or a "clinically isolated syndrome". Patients with an FCDE who show 'silent' magnetic resonance imaging lesions are at high risk of further clinical events and therefore of meeting the criteria for the diagnosis of clinically definite MS (CDMS). Here we review five Phase III trials, in which treatment with the following disease-modifying drugs (DMDs) was initiated at this early stage: interferon beta (ETOMS, CHAMPS, BENEFIT, and REFLEX) and glatiramer acetate (PreCISe). Differences in the design of the trials and their patient inclusion criteria limit comparisons. However, the proportion of placebo-treated patients who developed CDMS within 2 years was 38-45% across studies, and this rate was significantly reduced by DMD treatment. Conversion to McDonald MS was reported by only two of the trials: BENEFIT (2001 criteria) and REFLEX (2005 criteria). Around 85% of placebo-treated patients developed McDonald MS by 2 years in each, and again a beneficial effect of DMD treatment was seen. Overall, these studies support early use of DMDs to treat patients with an FCDE who are at high risk of conversion to CDMS. © 2013 The Authors.
2014
Freedman, M.S., Comi, G., De Stefano, N., Barkhof, F., Polman, C.H., Uitdehaag, B.M.J., et al. (2014). Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 3(2), 147-155 [10.1016/j.msard.2013.07.001].
File in questo prodotto:
File Dimensione Formato  
261.pdf

accesso aperto

Descrizione: Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice
Tipologia: PDF editoriale
Licenza: Creative commons
Dimensione 478.62 kB
Formato Adobe PDF
478.62 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1003832
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo